BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$4.16 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.15 -0.01 (-0.24%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
BCRX 4.16 0.00(0.00%)
Will BCRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BCRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BCRX
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
BCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains?
Other News for BCRX
First Week of BCRX December 20th Options Trading
Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Ironwood Pharma (IRWD)
BioCryst to Report First Quarter 2024 Financial Results on May 6
FYBR, BCRX and SABR are among after hour movers
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency